NCT02857270 2022-11-22A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerEli Lilly and CompanyPhase 1 Completed210 enrolled
NCT02981342 2019-11-20A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal AdenocarcinomaEli Lilly and CompanyPhase 2 Completed106 enrolled 24 charts
NCT02745769 2019-03-05A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted AgentsEli Lilly and CompanyPhase 1 Completed23 enrolled